Published online before print August 30, 2001, doi: 10.1161/hh1801.096263
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2001 American Heart Association, Inc.
Integrative Physiology |
Fc Receptor–Mediated Inhibitory Effect of Immunoglobulin Therapy on Autoimmune Giant Cell Myocarditis
Concomitant Suppression of the Expression of Dendritic Cells
From the Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Correspondence to Chiharu Kishimoto, MD, PhD, Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail kkishi{at}kuhp.kyoto-u.ac.jp
Abstract — In the present study, the mechanisms and importance of the Fc portion of immunoglobulin in experimental giant cell myocarditis were examined. Giant cell myocarditis was induced in rats by immunization of porcine cardiac myosin. Human intact immunoglobulin (1 g · kg-1 · d-1) or F(ab')2 fragments of human immunoglobulin (1 g · kg-1 · d-1) were administered intraperitoneally daily on days 1 to 21. Intact immunoglobulin administration significantly ameliorated myocarditis, but F(ab')2 fragments did not. The ribonuclease protection assay revealed that therapy with intact immunoglobulin, but not F(ab')2 fragments, suppressed the mRNA expressions of inflammatory and proinflammatory cytokines. Immunohistochemical analysis showed that therapy with intact immunoglobulin, but not F(ab')2 fragments, suppressed dendritic cell (DC) expression during both the early and the subsequent fulminant phases. Moreover, the early treatment of intact immunoglobulin until the 11th day or 14th day, when the expression of DCs was completely suppressed, ameliorated myocarditis. However, the late treatment of intact immunoglobulin beginning on day 15, when the expression of DCs had already been completed, failed to ameliorate the condition. An in vitro study showed that intact immunoglobulin, but not F(ab')2 fragments, suppressed the lipopolysaccharide-induced interleukin-1ß production associated with the downregulation of CD32 antigen (Fc
receptor II) expression. Thus, intact immunoglobulin therapy markedly suppressed myocarditis as a result of Fc receptor–mediated anti-inflammatory action, and the suppression of the disease was associated with the suppression of DCs, ie, the suppression of the initial antigen-priming process in experimental giant cell myocarditis.
Key Words: myocarditis • immunoglobulin • dendritic cells • cytokines • Fc receptors
This article has been cited by other articles:
 |
|
 |
|
  K. HooKim, S. deRoux, A. Igbokwe, A. Stanek, J. Koo, J. Hsu, M. R. Pincus, and M. H. Bluth IgG Anti-Cardiomyocyte Antibodies in Giant Cell Myocarditis Ann. Clin. Lab. Sci., January 1, 2008; 38(1): 83 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-a. Okabe, K. Shimada, M. Hattori, T. Murayama, M. Yokode, T. Kita, and C. Kishimoto Swimming reduces the severity of atherosclerosis in apolipoprotein E deficient mice by antioxidant effects Cardiovasc Res, June 1, 2007; 74(3): 537 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Staudt, P. Eichler, C. Trimpert, S. B. Felix, and A. Greinacher Fc{gamma} Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1684 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kishimoto A Novel Approach to the Suppression of Atherosclerosis by Fc{gamma} Receptor Blockade Circ. Res., November 24, 2006; 99(11): 1154 - 1155. [Full Text] [PDF]
|
|
|
|
|
|
P. Hernandez-Vargas, G. Ortiz-Munoz, O. Lopez-Franco, Y. Suzuki, J. Gallego-Delgado, G. Sanjuan, A. Lazaro, V. Lopez-Parra, L. Ortega, J. Egido, et al. Fc{gamma} Receptor Deficiency Confers Protection Against Atherosclerosis in Apolipoprotein E Knockout Mice Circ. Res., November 24, 2006; 99(11): 1188 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kishimoto, K. Shioji, and Z. Yuan Fc{gamma}IIB and Cardiovascular Inflammatory Disease Circ. Res., February 17, 2006; 98(3): e26 - e26. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nimata, T.-a. Okabe, M. Hattori, Z. Yuan, K. Shioji, and C. Kishimoto MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2514 - H2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Yuan, Y Liu, Y Liu, J Zhang, C Kishimoto, Y Wang, A Ma, and Z Liu Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade Heart, September 1, 2005; 91(9): 1203 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, M. Nimata, T.-a. Okabe, K. Shioji, K. Hasegawa, T. Kita, and C. Kishimoto Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1147 - H1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shioji, Z. Yuan, T. Kita, and C. Kishimoto Immunoglobulin treatment suppressed adoptively transferred autoimmune myocarditis in severe combined immunodeficient mice Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2619 - H2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liu, H. Nakamura, K. Shioji, M. Tanito, S.-i. Oka, M. K. Ahsan, A. Son, Y. Ishii, C. Kishimoto, and J. Yodoi Thioredoxin-1 Ameliorates Myosin-Induced Autoimmune Myocarditis by Suppressing Chemokine Expressions and Leukocyte Chemotaxis in Mice Circulation, September 7, 2004; 110(10): 1276 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H83 - H90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, Y. Liu, Y. Liu, J. Zhang, C. Kishimoto, Y. Wang, A. Ma, and Z. Liu Peroxisome proliferation-activated receptor-{gamma} ligands ameliorate experimental autoimmune myocarditis Cardiovasc Res, September 1, 2003; 59(3): 685 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, C. Kishimoto, H. Sano, K. Shioji, Y. Xu, and M. Yokode Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H899 - H906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al. Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy Circulation, November 5, 2002; 106(19): 2448 - 2453. [Abstract] [Full Text] [PDF]
|
|